XML 79 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Jan. 26, 2017
$ / shares
shares
Dec. 31, 2016
USD ($)
Aug. 29, 2016
director
$ / shares
shares
Sep. 30, 2013
USD ($)
item
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
item
Related Party Transactions                    
Common stock value $ 310,635   $ 19,944     $ 310,635   $ 310,635   $ 19,944
Chief Executive Officer | License Agreement with Yale                    
Related Party Transactions                    
Number of inventors of the patents licensed from Yale | item         1          
Common shares issued | shares         250,000          
Percent of Company's outstanding equity fully diluted         5.10%          
Common stock value         $ 152          
Recognized research and development expenses           32 $ 0 38 $ 4  
Payments to related party $ 0   $ 0     $ 0   $ 0   $ 0
Shareholders and members of the Board of Directors | Guarantor and Co-Guarantor Warrants | Guarantor and Co-Guarantor Warrants                    
Related Party Transactions                    
Common shares issued | shares   107,500                
Exercise price of warrants (per share) | $ / shares   $ 9.2911                
Equity Investment | Kleo Pharmaceuticals, Inc.                    
Related Party Transactions                    
Shares of Kleo common stock purchased | shares       3,000,000            
Price per share | $ / shares       $ 1.00            
Additional shares of Kleo common stock purchased | shares       5,500,000            
Number to designate to Kleo's board of directors | director       2            
Shares of Kleo common stock purchased from Chief Executive Officer | shares       500,000            
Ownership percentage 33.00%         33.00%   33.00%    
Majority Shareholder | Biohaven Pharmaceuticals, Inc.                    
Related Party Transactions                    
Number of founders | item                   3
Equity share percentage owned by each founders     33.33%             33.33%
Ownership interest acquired     100.00%             100.00%
Aggregate purchase consideration     $ 595             $ 595
IPO | Biohaven Pharmaceuticals, Inc.                    
Related Party Transactions                    
Repayment of principal amount to related party $ 595             $ 595    
Repayment of accrued interest amount to related party               $ 9